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Abstract
Studies fail to find uniform effects of age-related or induced hypogonadism on human sexual
function. We examined the effects of induced hypogonadism on sexual function in healthy men
and women and attempted to identify predictors of the sexual response to induced hypogonadism
or hormone addback. The study design used was a double-blind, controlled, crossover (self-as-
own control). The study setting was an ambulatory care clinic in a research hospital, and the
participants were 20 men (average ± SD age = 28.5 ± 6.2 years) and 20 women (average ± SD age
= 33.5 ± 8.7 years), all healthy and with no history of psychiatric illness. A multidimensional scale
assessing several domains of sexual function was the main outcome measure. Participants of the
study received depot leuprolide acetate (Lupron) every 4 weeks for 3 months (men) or 5 months
(women). After the first month of Lupron alone, men received (in addition to Lupron) testosterone
enanthate (200 mg intramuscularly) or placebo every 2 weeks for 1 month each. Women received
Lupron alone for 2 months, and then, in addition to Lupron, they received estradiol and
progesterone for 5 weeks each. The results of the study: in women, hypogonadism resulted in a
significant decrease in global measures of sexual functioning, principally reflecting a significant
decrease in the reported quality of orgasm. In men, hypogonadism resulted in significant
reductions in all measured domains of sexual function. Testosterone restored sexual functioning
scores in men to those seen at baseline, whereas neither estradiol nor progesterone significantly
improved the reduced sexual functioning associated with hypogonadism in women. Induced
hypogonadism decreased sexual function in a similar number of men and women. No predictors of
response were identified except for levels of sexual function at baseline. In conclusion, our data do
not support a simple deficiency model for the role of gonadal steroids in human sexual function;
moreover, while variable, the role of testosterone in sexual function in men is more apparent than
that of estradiol or progesterone in women.
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INTRODUCTION
Studies of the effects of hypogonadism on sexual functioning in women have been
confounded by the conditions under which hypogonadism occurs, including aging, surgical
procedures, and coexisting gynecologic pathologies. In young men, decreased sexual
functioning secondary to hypogonadism is more consistently demonstrated (Bagatell et al,
1994); however, the reductions are not uniformly observed, and predictors of the sexual
response to hypogonadism or androgen replacement have not been identified. While
imperfect in modeling natural conditions, hormone manipulation paradigms can eliminate
many of the confounds that obscure the relationship between hormones and sexual function.
In this study, we take advantage of two studies of the effects of induced hypogonadism on
mood in young, healthy men and women, and ask whether similar hormonal manipulations
alter sexual function.
A role for sex steroids in the regulation of sexual function in men and women has been
inferred from several observations. First, therapeutic trials, many of which were placebo-
controlled, reported the beneficial effects of sex hormone therapy in men and women in
whom hypogonadism was secondary to medical or surgical castration (Floter et al, 2002;
Shifren et al, 1985, 2000; Simon et al, 2005; Sherwin et al, 1985; Sherwin and Gelfand,
1987; Braunstein et al, 2005; O’Carroll et al, 1985; Anderson et al, 1999; Bhasin, 2000;
Bagatell et al, 1994; Dennerstein et al, 1980; Davidson et al, 1979), reproductive senescence
(Nathorst-Boos et al, 1993b, 2006; Sarrel, 1990, 1998; Wiklund et al, 1993; Myers et al,
1990; Sarrel et al, 1998; Lobo et al, 2003; Sherwin, 1991; Wang et al, 2000; Gray et al,
2005; Steidle et al, 2003; Seftel et al, 2004; Guay et al, 1995), or concurrent medical
conditions (eg Kallman’s syndrome or HIV) (Wang et al, 2000; O’Carroll et al, 1985;
Snyder et al, 2000; Anderson et al, 1999; Arlt et al, 1999; Rabkin et al, 2000, 2006;
Johannsson et al, 2002; Carani et al, 2005). These data suggest (albeit indirectly) that
deficiencies of sex hormones could underlie a decrease in sexual function in both men and
women. Second, some basal hormone studies have observed correlations between blood
levels of sex steroids and sexual functioning, while other studies have observed lower sex
hormone levels in subjects with decreased sexual function compared with asymptomatic
control groups (Schiavi et al, 1991; Cawood and Bancroft, 1996; Santoro et al, 2005; Basar
et al, 2005; Modelska et al, 2004; Travison et al, 2006; Beutel et al, 2005; Kennedy et al,
1997; Nyunt et al, 2005; Dennerstein et al, 1994, 2002; Slob et al, 1996; Adams et al, 1978;
Bancroft et al, 1980; Meuwissen and Over, 1992; Doering et al, 1974). Finally, several
longitudinal studies have demonstrated the reduction of sexual function under the following
circumstances: after medical or surgical castration; after the development of hypogonadism
secondary to a variety of medical illnesses; after the administration of medications that
inhibit sex hormone production (Marberger et al, 2006); and during age-related reproductive
senescence (Dennerstein et al, 2002; Koster and Garde, 1993).
Despite these findings, the role of gonadal steroids in the regulation of sexual function in
humans remains controversial for several reasons. First, the results of therapeutic trials are
difficult to interpret since hormone therapy may have effects independent of those on sexual
function. For example, mood, energy, muscle mass, and strength improve with androgen
therapy and might, therefore, contribute indirectly to the observed beneficial effects of
androgens on sexual functioning (Grinspoon et al, 2000). Second, the results of basal
hormone studies are inconsistent, since men and women with low sex hormone levels do not
uniformly report low levels of sexual function (Travison et al, 2006; Santoro et al, 1996;
Burger et al, 1995, 1999, 2000; Leiblum et al, 2006; Sternbach, 1998; Bachmann et al, 1985;
Greendale et al, 1996; Davidson et al, 1983; Vermeulen, 2001). Finally, a substantial
proportion of both men and women (30–50%) report no change in libido after medical or
surgical castration despite obvious losses of reproductive endocrine function (Bagatell et al,
Schmidt et al. Page 2
Neuropsychopharmacology. Author manuscript; available in PMC 2009 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
1994; Bremer, 1959; Dennerstein et al, 1977, 2002; Chakravarti et al, 1977; Tauber, 1940;
Elit et al, 2001; Madalinska et al, 2005; Zussman et al, 1981).
Several characteristics could influence the impact of declining or suppressed gonadal steroid
secretion on sexual functioning, including the magnitude of the decrease in sex hormone
levels from baseline, the level of hormone during hypogonadism (ie below a threshold of
hormone levels at which impaired sexual function occurs), sex, age, duration of
hypogonadism, and baseline phenotype (eg level of sexual function), as well as the presence
of concurrent symptoms such as depression (Isidori et al, 2005; Beutel et al, 2005; Cawood
and Bancroft, 1996; Nilsson et al, 1995; Kratzik et al, 2004; Finkelstein et al, 1998; Schiavi
and White, 1976; Schiavi et al, 1994). Indeed, in a preliminary study using an
undimensional evaluation of libido, we observed that baseline levels of sexual functioning
predicted the response to hypogonadism and hormone replacement in a group of men with
GnRH agonist-induced hypogonadism (Schmidt et al, 2004). These observations are
important clinically as they could predict those individuals in whom hormone therapy would
improve sexual function.
In this study, we attempted to examine the role of gonadal steroids in human sexual
functioning as follows: first, we assessed the impact of the acute short-term induction of
hypogonadism on sexual functioning. Second, we evaluated potential sex differences in the
response to induced hypogonadism. Finally, we examined the impact of several other
variables that might predict a differential response to hypogonadism or hormone therapy in
humans, including age, mood symptoms, and hormone levels. Our main hypothesis was that
induced hypogonadism would impair sexual functioning across multiple domains in groups
of men and women. A secondary hypothesis was that considerable variability would be
demonstrated in the impact of hypogonadism on sexual functioning in men and women
(Wallen, 1990, 2001; Herzog et al, 2005; Zehr et al, 1998).
METHODS
Subject Selection
Men (between age 18 and 45 years) and women (between age 18 and 55 years) were
recruited through advertisements in local newspapers or referred from the NIH Normal
Volunteer Office, and participated between November 1994 and March 2003. All were
participants in a larger study examining the effects of GnRH agonist-induced hypogonadism
and sex hormone replacement on measures of mood and brain function. Given the original
focus of this study, in women we evaluated the effects of the two principal ovarian steroids,
estradiol and progesterone, whereas the effects of testosterone were evaluated in men only.
Estradiol, testosterone, and progesterone (or its neurosteroid metabolites) all have been
implicated in the regulation of appetitive behaviors including sexual motivation in both
animals and humans (Frye, 2007; Evans and Foltin, 2006; Dreher et al, 2007). All
participants were medication free and free of significant medical illness (current or in the
past 2 years) confirmed by history, physical examination, and routine laboratory tests.
None of the men and women reported problems with their mood, sleep, sexual function, or
sexual relationships. Women reported regular menstrual cycle function (21–35 days). The
absence of current or past psychiatric illness was confirmed by a structured psychiatric
diagnostic interview (Spitzer et al, 1990). Additionally, all subjects completed daily visual
analog scale self-ratings (sadness, anxiety, and irritability) for at least 2 months to exclude
the presence of premenstrual mood symptoms in women or other mood disturbances.
The protocol was approved by the National Institute of Mental Health Intramural Research
Board, and written informed consent was obtained from all subjects. Subjects were paid for
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their participation in this protocol according to the guidelines of the NIH Normal Volunteer
Office.
Procedure
Hormonal manipulation protocol—All women received 3.75 mg of depot Lupron
(leuprolide acetate, purchased from TAP Pharmaceuticals, Chicago, IL) by intramuscular
injection every 4 weeks for 5 months (Figure 1). Lupron alone was administered for the first
8 weeks. All women then received, in addition to Lupron, 17 β estradiol (0.1 mg/ day) (E)
by skin patch (Alora, active and placebo patches were supplied by Watson Pharmaceuticals,
Salt Lake City, UT) or progesterone suppositories (200 mg b.i.d.) (P) (NIH Pharmacy,
Bethesda, MD) for 5 weeks each. The two replacement regimens were separated by a 2-
week washout period.
All men received 7.5 mg of depot Lupron by intramuscular injection every 4 weeks for 3
months. Lupron alone was administered for the first 4 weeks. Subjects then received, in
addition to Lupron, testosterone enanthate (200 mg) (T) or placebo (1 ml sesame oil) given
by intramuscular injection every 2 weeks for 1 month. A placebo comparison was included
in men to blind the timing of the addition of testosterone, whereas in women no placebo
phase was included since the order of estradiol and progesterone addback was randomly
assigned.
In both men and women, the order of receiving hormone replacement (ie, T vs placebo in
men, and E vs P in women) was randomly assigned and counter-balanced.
Subjects were seen at the NIMH clinic at least every 2 weeks throughout the study, and
blood samples were obtained and symptom rating scales were completed. Both subjects and
raters (NH, PJS) were blinded to the order of replacement. Blood samples were employed
solely to confirm hormone levels during each of the pharmacologically induced hormone
conditions (see Table 2). Individuals came into the clinic at approximately the same time
during the study, although the time of the day for each visit varied across individuals. Blood
samples were centrifuged, aliquoted, and stored at −70°C until time of assay.
Outcome Measures
Sexual functioning was evaluated by a uniquely modified version of the Derogatis Interview
of Sexual Functioning-Self Report (DISF-SR) (Derogatis, 1997), a multidimensional scale
with separate forms designed for men and women. The DISF-SR scale was selected for this
study because it sampled several domains of sexual function. Additionally, in contrast to the
majority of other measures of sexual function, the DISF-SR was available in forms adapted
for both men and women and, therefore, potential sex differences could be evaluated.
Finally, the reliability and validity of DISF-SR (and other scales measuring sexual function)
have been determined by comparing scores between symptomatic and asymptomatic
samples; however, this study employed a repeated measure, self-as-own design;
consequently, the capability of the scale to distinguish normal from abnormal sexual
function was less of a concern. Questions focus on five domains (ie, subscales) of sexual
functioning: (1) sexual cognition and fantasy (eg erotic thoughts and dreams), (2) sexual
arousal (eg level of arousal during sexual behaviors), (3) sexual behavior and experience (eg
masturbation, foreplay, and intercourse), (4) quality of orgasm, and (5) sexual drive and
relationship (eg level of satisfaction with sexual relationships). We requested and were given
permission to modify the DISF-SR specifically for this study by the author and copyright
holder, Leonard R Derogatis, PhD. Such permission used by the authors (PJS, DRR) should
in no way be construed as an endorsement of this approach to measurement. The DISF was
modified from the original for this study as follows. First, the sampling interval within
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which sexual function is measured was reduced from a 30-day to a 7-day interval. Second,
the scale was converted from a nine-point Likert-type scale (0–8) to a 100 mm visual analog
scale (0–100) (range––not at all to very frequently). Finally, a seventh question was
introduced in section IV (quality of orgasm) of the male version to examine feelings of
closeness and togetherness with partner, an item that was present in the female scale and
also relevant to male sexual function. The modified scale has both a total score and
individual domain scores (subscale) as follows: maximum total scores of 2500 in women
and 2600 in men, maximum scores for each domain of 500, except for quality of orgasm
(no. 4––score of 600 in women and 700 in men), and sexual drive (no. 5––score of 400 in
both men and women) (Figure 2).
The modified version maintained the same five domains as the original, and except for one
question (mentioned above), the remaining 25 questions were the same (in both female and
male interviews). The DISF was administered at baseline (start date of Lupron) in both men
and women. In men, the DISF also was administered during the last weeks of placebo and T
replacement; whereas in women, the DISF was administered at the end of Lupron alone
(hypogonadism) and during the last week of each hormone replacement condition (E and P).
Symptom rating data during the first month were not included in the analysis since steroid
levels increase (or ‘flare’) transiently after the first injection of Lupron. Additionally, to
evaluate coexisting mood symptoms all participants completed the Beck Depression
Inventory (BDI) (Beck et al, 1961) at the same time that the DISF was completed.
Statistical Analysis
In both women and men, serum hormone levels, BDI, and total DISF scores at each time
point were compared by analysis of variance with repeated measures (ANOVA-R; Systat,
SPSS, Chicago, IL), with hormone condition (women [four levels]: baseline, hypogonadal,
E, and P; men [three levels]: baseline, hypogonadal, and T) as the within-subjects variable.
Additionally, in both men and women we examined the effects of hormone condition on
individual domains of sexual functioning by performing separate ANOVA-Rs on each of the
DISF subscales (ie nos. 1–5).
To examine possible sex differences in response to hypogonadism, Z-scores were calculated
for baseline and hypogonadal DISF scores (ie, total and individual subscale scores) in the
women and compared with those in men by ANOVA-R with sex as the between-subjects
variable and hormone condition (baseline and hypogonadal) as the within-subjects variable.
Z-scores were calculated using the average and standard deviations of the baseline DISF
scores in each sex to permit comparisons across men and women despite differences in total
maximum DISF scores. Additionally, we operationally defined a substantial decline in
sexual function as a 50% or greater reduction in the total DISF score relative to baseline
scores. This criterion was intended to serve as a proxy for a clinically significant decrease in
sexual function (Alexander et al, 2004) and was based on a similar threshold employed in
pharmacologic studies of depression, in which a 50% improvement in rating scores is
considered to be clinically significant. We compared the number of men and women who
experienced a 50% or greater reduction (relative to baseline) in their total DISF scores by χ2
analysis. We performed an identical analysis employing a less conservative 30% cutoff
score as the threshold.
In a prior report (Schmidt et al, 2004) with a larger sample of men (ie n = 31), 20 of whom
participated in this study, men who received placebo first and, therefore, were exposed to
two consecutive months of hypogonadism reported greater declines in sexual function
during hypogonadism than those men receiving T replacement first (ie the first month of
Lupron alone was followed by 1 month of T prior to the third month during which they
received Lupron plus placebo). Thus, we repeated our analyses of sex differences in DISF
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scores after hypogonadism with only those men who were exposed to two consecutive
months of hypogonadism to match (and control for differences in) the duration of
hypogonadism in the women in this study.
In our earlier report, in which we employed a multi-symptom inventory in the male subjects
of the current study, we also observed that baseline levels of sexual interest predicted
subsequent behavioral response to both hypogonadism and T replacement (Schmidt et al,
2004). To replicate these observations with a more comprehensive measure of sexual
function in men and to determine if these observations could be extended to women, we first
assigned subjects to one of two categories defined by their baseline DISF total scores and
then compared subjects in the lowest (n = 6) and highest (n = 6) tertile baseline scores. DISF
scores (total and subscale) were re-analyzed within each sex by ANOVA-R, with baseline
total DISF score (low vs high) as the between-subjects variable and hormonal condition as
the within-subjects variable.
Finally, men and women were grouped for comparison as follows: (1) those with a 50% or
greater reduction in the total DISF scores during hypogonadism compared with baseline and
(2) those with the highest and lowest tertiles of baseline DISF scores (as described above).
We examined whether these differences in sexual function were associated with specific
characteristics at baseline, during hypogonadism, or that changed between baseline and
hypogonadism. Two-tailed Student’s t-tests (all t-tests had Bonferroni corrections for the
number of comparisons made unless indicated) were performed comparing the following
baseline measures: age; blood hormone levels (ie, men: total T, free T, E, and
dihydrotestosterone [DHT]; women: total T, E, and P), including measures at baseline,
during hypogonadism, and the difference (Δ) between measures at baseline and during
hypogonadism; and BDI scores at baseline, during hypogonadism, and the change in BDI
scores between baseline and hypogonadism. Pearson correlation coefficients were employed
to investigate possible relationships between changes in DISF scores and changes in blood
hormone levels.
RESULTS
Subject Characteristics
In total, 20 men ranging in age from 22 to 42 years (mean ± SD, 28.5 ± 6.2 years) and 20
women ranging in age from 19 to 47 years (mean ± SD, 33.5 ± 8.7 years) participated in the
study. All participants were Caucasian except for two African-American women. Eleven
men received placebo first and, therefore, were exposed to two consecutive months of
hypogonadism as were all 20 women. All subjects were sexually active, and their marital
status was as follows: men––single (n = 12), married (n = 6), and divorced (n = 2);
women––single (n = 13), married (n = 5), and divorced (n = 2). In women, there were no
significant effects of hormone condition on BDI scores (ANOVA-R F3,57 = 0.5, p = NS),
whereas in men a significant effect of hormone condition on BDI scores was observed
(ANOVA-R F2,38 =3.7, p =0.04), which reflected a small but statistically significant increase
in BDI scores during the hypogonadal state (Table 1). This increase in BDI score reflected
the influence of two men who developed clinically significant mood symptoms and had BDI
scores of 14 and 6, respectively, during hypogonadism (consistent with data in the larger
group of subjects reported previously) (Schmidt et al, 2004).
DISF Symptom Ratings
Comparisons across hormone conditions in women and men—In women,
induced hypogonadism significantly decreased DISF scores compared with those at baseline
(Table 1). DISF scores during hypogonadism did not differ from those during either E or P.
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All DISF subscale scores also showed a reduction during hypogonadism, E, and P compared
with baseline; however, the only decrease that met statistical significance after adjustment
for five comparisons (ie, the five subscales) was subscale four (quality of orgasm). As
observed with the total DISF scores, the subscale scores during hypogonadism, E, and P did
not differ significantly.
In men, total DISF scores during hypogonadism were significantly decreased compared with
scores during both baseline and T. All five subscale scores significantly decreased during
hypogonadism compared with baseline conditions and during hypogonadism compared with
T (see Table 1).
We observed identical patterns of results when we repeated these analyses after excluding
those men (n = 1) and women (n = 5) over 40 years of age.
Comparisons between men and women during baseline and hypogonadism—
Standardized total DISF scores (ie, Z-scores) were significantly higher in men compared
with women during both baseline and hypogonadism and significantly decreased in both
sexes during hypogonadism compared with baseline. Each of the individual DISF subscales
demonstrated a similar significant effect of hormone condition (decreased during
hypogonadism), and in scales nos. 2 and 4 (ie, arousal and orgasm), we observed significant
effects of sex (higher in men) and a sex by hormone condition interaction, reflecting greater
decline in men than women during hypogonadism. An identical pattern of effects was
observed when the nine men who received T replacement before placebo were excluded
from the analysis.
Eight men (40%) and seven women (35%) experienced a 50% or greater decline in total
DISF scores during hypogonadism: (χ2 = 0.12, p = 0.7); similarly, 12 men (60%) and 14
women (70%) experienced a 30% or greater decline in total DISF scores during
hypogonadism. Five of the eight men who experienced a 50% or greater decline in total
DISF received placebo first.
Comparisons between those with high and low baseline DISF scores—Women
with low and high total DISF scores at baseline had significantly different responses to
induced hypogonadism (Figure 2). No significant effects of hormone condition were
observed in the low baseline symptom group (t30 (range) = 1.0–1.4, p = NS), with no
significant differences between hypogonadism, E, and P compared with baseline. In
contrast, the women with high total DISF scores at baseline had significantly lower scores
during hypogonadism, E, and P compared with baseline conditions, (t30 (range) = 4.6–5.4, p
< 0.01).
In men, a similar pattern of effects was observed, with the absence of significant differences
(between hypogonadism and baseline or T) in the low baseline symptom group (t20 (range)
= 0.1–1.6, p = NS), whereas in the high baseline symptom group significantly lower DISF
scores were observed during hypogonadism compared with baseline and T conditions (t20 =
6.1 and 7.5, respectively, p < 0.01).
As a caveat, when data were re-analyzed using baseline DISF scores as a covariate, the
significance of the effect of hormone condition was reduced to marginally significant levels
(p = 0.05 and 0.01 (women and men, respectively)).
Mood and Hormonal Measures
Characteristics of those with and without a clinically significant response to
hypogonadism—Women with and without a 50% or greater reduction in total DISF
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scores were not distinguished by any variables, including total T and P (Student’s t-values
ranged from 0.9 to 1.0), with the exception of significantly lower baseline plasma E levels
(in those women with a 50% reduction in DISF scores) (Student’s t17 = 2.8, p = 0.013) and a
significantly greater decline in plasma E levels from baseline to hypogonadism in those
without a 50% decrease (Student’s t17 = 15.9, p = 0.02). These findings reflected the
presence of outlier values in the women without a 50% decrease that spuriously elevated
mean baseline E levels. When three women with luteal phase plasma levels of E (ie, > 100
pg/ml) were eliminated from the analysis, there were no differences between the groups.
There were also no differences in plasma E levels between groups of women during
hypogonadism (Student’s t17 = 1.3, p = NS).
Similarly, no significant differences were observed between those men with and without a
50% or greater reduction in total DISF scores during hypogonadism (relative to baseline) in
the following measures: age; BDI scores (at baseline, during hypogonadism, or the change
in BDI score from baseline to hypogonadism); and plasma hormone levels (total and free T,
DHT, and E) at baseline or during hypogonadism as well as the difference in plasma
hormone levels between baseline and hypogonadism (Δ). (Student’s t-values ranged from
0.7 to 1.0).
Finally, no baseline differences were observed between the high and low baseline symptom
groups in either men or women (Student’s t-values ranging from 0.5 to 1.0).
Hormone measures of experimental condition—Blood hormone levels confirmed
the creation of the intended hormone conditions (Table 2). As expected, blood levels of T in
women remained suppressed relative to baseline for the duration of the study (ie, despite E
or P addback).
Hormonal correlates of DISF scores—No significant correlations were seen between
the changes in hormone levels across conditions and the corresponding change in total DISF
scores in either men or women.
DISCUSSION
Our hypotheses were that induced hypogonadism would impair sexual functioning across
multiple domains and that there would be considerable variability in the impact of
hypogonadism on sexual functioning in both men and women. Both of these hypotheses
were confirmed, albeit with sex differences in the domains of sexual functioning influenced
by induced hypogonadism. The findings of this study have implications for clinicians’
expectations about the impact of hypogonadism on an individual’s sexual function and,
possibly, for the selection of men and women who would be appropriate candidates for
hormone therapies targeted at improving sexual function. First, in women, short-term
induced hypogonadism was associated principally with a significant decrease in the reported
quality of orgasm, whereas in men, hypogonadism significantly reduced all domains of
sexual function measured by the DISF. In men, testosterone replacement restored sexual
function to that observed at baseline, whereas in women, neither estradiol nor progesterone
replacement reversed the reduction in sexual functioning caused by hypogonadism. Despite
the reduction in sexual function observed on a group basis, only 40% of men and 35% of
women reported substantial decreases in sexual function during induced hypogonadism (ie,
50% or greater decline in total DISF scores relative to baseline). Second, we observed no
sex differences in the proportion of participants who responded with a substantial decline in
sexual function during hypogonadism. Third, those participants with and without a
significant decline in DISF scores during hypogonadism were not distinguished by any
measure, including baseline mood symptom ratings (ie, BDI scores) and both baseline and
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post GnRH agonist hormone measures. Finally, men and women with high baseline DISF
scores responded differently to hypogonadism than those with lower baseline DISF scores.
Thus, levels of sexual function at baseline (ie, total DISF score) in both men and women
predicted the magnitude of the decline in sexual function during hypogonadism and, in men,
the improvement in sexual function after testosterone replacement. This study was designed
to evaluate the effects of hypogonadism and sex steroid replacement on measures of mood;
sexual function was not a primary outcome measure. However, the hormone manipulations
performed represented a unique opportunity to examine the effects of hypogonadism (albeit
short term) on measures of sexual function in young healthy men and women. The absence
of a T replacement arm in women and the relatively small sample sizes limit our conclusions
about the source of the decline in libido in women. Nonetheless, short-term hypogonadism
was associated with a decline in measures of sexual function in both men and women.
In men, the reduced sexual function during hypogonadism was restored to baseline levels by
testosterone replacement. These data in men are consistent with previous reports of impaired
sexual functioning in hypogonadal men and the restoration of sexual function with
testosterone replacement (Bhasin, 2000; Guay et al, 1995; Anderson et al, 1999; Snyder et
al, 2000; Seftel et al, 2004; Isidori et al, 2005; Steidle et al, 2003; Gray et al, 2005;
O’Carroll et al, 1985; Wang et al, 2000; Davidson et al, 1979; Kwan et al, 1983). The
observed changes in sexual function in men during induced hypogonadism occurred
independent of significant changes in mood symptoms (an increase in negative mood was
reported in only two men). The reduction in global sexual function could be related to loss
of testosterone, its 5 α-reduced metabolite DHT, estradiol (synthesized from testosterone
within the brain by aromatase), or one of testosterone’s neurosteroid metabolites such as
androsterone. Indeed, androsterone levels are implicated in the reduced libido observed in
this trial. In a subsample of these men in whom lumbar punctures were performed, we
observed that CSF androsterone levels but not CSF measures of T or DHT correlated with
the symptom of decreased sexual function (Bloch et al, 2006).
In women, we observed a similar effect of hypogonadism on total DISF scores; however, in
contrast to the effects of testosterone in men neither estradiol nor progesterone replacement
restored sexual function to levels reported at baseline. The failure of estradiol to enhance
sexual function is consistent with some (Nathorst-Boos et al, 1993a; Alexander et al, 2004;
Lobo et al, 2003; Sherwin, 1985; Myers et al, 1990), but not all (Dennerstein et al, 1980,
2002; Finkelstein et al, 1998; Sarrel, 1990, 1998; Sarrel et al, 1998; Sherwin, 1991; Nathorst-
Boos et al, 1993b; Wiklund et al, 1993), studies reporting an association between estradiol
levels and sexual function. While we did observe sexual function to decline in association
with hypogonadism-induced decreases in ovarian estradiol secretion (perhaps consistent
with earlier studies), sexual function was not restored by estradiol replacement. Blood levels
of both estradiol and progesterone increased during each of their respective replacement
conditions, but only slight nonsignificant increases in DISF scores accompanied these
changes. Nonetheless, it is possible that had we studied a larger sample of women with
decreased libido, or had we employed higher doses or provided a longer duration of therapy
of estradiol (or possibly progesterone), a larger impact on sexual function would have been
observed. The doses employed in this study, however, were adequate to reduce hot flushes
(estradiol and progesterone) and self-reports of vaginal dryness (estradiol only). While no
statistically significant effects of estradiol on sexual functioning were observed, an
improvement in sexual function after estradiol was observed and, therefore, a type II error
cannot be ruled out. Blood levels of both testosterone and DHT remained suppressed in
women throughout all three hormone conditions in which DISF scores were reduced relative
to baseline. Blood testosterone levels were decreased by approximately 30% during Lupron-
induced hypogonadism compared with baseline and, therefore, changes in testosterone (or
one of its androgen or neurosteroid metabolites) could mediate the observed decline in
Schmidt et al. Page 9
Neuropsychopharmacology. Author manuscript; available in PMC 2009 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
sexual function and quality of orgasm in women (Simon et al, 2005; Sherwin et al, 1985;
Lobo et al, 2003; Nathorst-Boos et al, 2006; Braunstein et al, 2005; Sherwin and Gelfand,
1987; Shifren et al, 2000; Floter et al, 2002; Davis et al, 2006; Leiblum et al, 2006; Santoro
et al, 2005). However, since testosterone was not administered to women in this study, we
only can speculate about this possible relationship.
The robust decline in the reported quality of orgasm during hypogonadism contrasts with the
results of many, but not all, studies examining the effects of testosterone therapy on domains
of sexual function in women. Studies by Sherwin et al (1985) and Floter et al (2002)
observed testosterone to enhance arousal and motivational aspects of sexual function in
hypogonadal women, but neither quality of orgasm nor sexual behavior was increased.
Although the Sherwin data (Sherwin et al, 1985) suggested that orgasm and sexual behavior
were influenced less by androgens, more recent studies employing transdermal testosterone
have observed improvements in all domains of sexual function, including orgasm and
frequency of intercourse (Simon et al, 2005; Shifren et al, 2000; Braunstein et al, 2005;
Nathorst-Boos et al, 2006).
Despite significant changes on a group basis, only 35% and 40% of women and men,
respectively, experienced a substantial (50% or greater) decline in DISF scores during
hypogonadism. At first glance, the proportion of participants in whom hypogonadism
reduced sexual function seems remarkably small; however, these data are consistent with
several prior studies in which rates of moderate to severe sexual dysfunction ranged from
20% to 50% in women postmenopause or post-oophorectomy (with studies of women post-
oophorectomy reporting higher rates of clinically significant loss of libido compared with
the natural menopause) (Leiblum et al, 2006; Bremer, 1959; Dennerstein et al, 1977, 2002;
Chakravarti et al, 1977; Koster and Garde, 1993; Elit et al, 2001; Madalinska et al, 2005;
Bachmann et al, 1985; Teplin et al, 2006). The rate of reduced sexual function in men (40%)
is lower than the rates of post-castration loss of sexual function of 50% or greater reported
by some case series (Bagatell et al, 1994; Bremer, 1959; Tauber, 1940; Basaria et al, 2002).
Our data demonstrate that induced hypogonadism, at least short term, does not result in a
clinically significant loss of sexual function in all men and women. Thus, as with many
other non-reproductive behaviors, there is a differential response of sexual function to
changes in reproductive function, with only a proportion of subjects experiencing a
significant change in behavior despite a similar decrease in sex steroid hormone secretion.
These data also could explain the findings of several treatment studies in which sex hormone
therapy was not uniformly effective in enhancing libido (Seftel et al, 2004; Isidori et al,
2005; Davidson et al, 1979).
Several factors have been reported to modify the behavioral response to declining or loss of
sex steroid secretion, including age, sex, extent of hormone suppression, quality of
relationship with partner, coexisting stress or mood symptoms, or levels of adrenal
hormones (Gray et al, 2005; Koster and Garde, 1993; Beutel et al, 2005; Cawood and
Bancroft, 1996; Bachmann et al, 1985; Davidson et al, 1983; Basar et al, 2005; Nilsson et
al, 1995; Kratzik et al, 2004; Finkelstein et al, 1998; Schiavi and White, 1976; Schiavi et al,
1994). However, with the exception of baseline DISF scores, no baseline characteristic was
associated with the level of impaired libido during hypogonadism, including age (although
all participants were of a similar young age), depression scores during hypogonadism,
hormone levels during either baseline or hypogonadal conditions, and change in hormone
levels across conditions. Men and women with higher baseline levels of sexual function
(high group) experienced the greatest loss of sexual function during hypogonadism;
however, these participants were not distinguished by any other characteristic measured in
this study. These data are consistent with and extend our previous observations in men
(Schmidt et al, 2004) as well as those in animals by Grunt and Young (1952, 1953), who
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reported that baseline levels of sexual activity predicted the response to castration and
testosterone replacement in male guinea pigs. A floor effect may have prevented detection
of a decline in DISF scores during hypogonadism in the low symptom group. Baseline DISF
scores clearly contributed to the results we observed; nonetheless, the effect of hormone
condition cannot solely be attributed to those with elevated baseline DISF scores. An
important role for sex steroids in at least some men and women is suggested both by the loss
of sexual function in men and women in the high baseline sexual function groups and by the
restoration of normal sexual function by testosterone in the high baseline sexual function
men (but not in the low symptom groups despite comparable changes in sex steroids). Thus,
our data and those of others (Gray et al, 2005) suggest that a behavioral phenotype could
predict a disparate response to changes (either decreases or increases) in sex steroid
secretion. This phenotype could contribute to the heterogeneity of the changes in sexual
function during reproductive aging in both men and women.
This study has several limitations: first, the duration of hypogonadism was relatively brief,
and it is possible, therefore, that a longer duration of hypogonadism would have resulted in a
larger proportion of men and women developing clinically significant losses of sexual
function or different patterns of loss with respect to specific domains of sexual function.
Indeed, in our earlier report (Schmidt et al, 2004), in a larger sample, those men exposed to
two consecutive months of hypogonadism reported a greater decline in sexual function.
Nonetheless, the relative proportion of women affected in this study is comparable to rates
of significant loss of sexual function in previous studies in women after oophorectomy or
natural menopause (Leiblum et al, 2006; Dennerstein et al, 1977, 2002; Chakravarti et al,
1977; Koster and Garde, 1993; Elit et al, 2001; Madalinska et al, 2005). Indeed, even in
men, studies have reported that a loss of sexual function is not observed in 100% of
hypogonadal men (Bagatell et al, 1994; Bremer, 1959). Second, although we controlled for
several factors that could contribute to sexual function, including age, concurrent symptoms,
and sex, we did not obtain detailed information about the quality of the relationships in
participants (Bachmann et al, 1985). We also did not measure adrenal hormones (cortisol
and dehydroepiandrosterone (DHEA)) (Basar et al, 2005), although neither baseline DHEA
nor cortisol secretion would be predictably altered by GnRH agonist treatment. Finally, we
studied young healthy men and women, and the rate of sexual dysfunction after
hypogonadism could be higher in older subjects or in those with concurrent medical
illnesses. Thus, our findings should not be generalized to older men and women.
Future studies should investigate other possible biological or environmental contributors to
the difference in behavioral response to permit a better characterization of this hormonally
vulnerable group of men and women.
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Figure 1.
All women received 3.75 mg of depot Lupron (leuprolide acetate; TAP Pharmaceuticals,
Chicago, IL) by intramuscular injection every 4 weeks for 5 months. The first injection of
Lupron was administered during the follicular phase between days 2–6 after the onset of
menses. Lupron alone was administered for the first 8 weeks. All women then received, in
addition to Lupron, 17 β estradiol (0.1 mg/day) (E) by skin patch (Alora; Watson
Pharmaceuticals, Salt Lake City, UT) or progesterone suppositories (200 mg b.i.d.) (P) (NIH
Pharmacy, Bethesda, MD) for 5 weeks each. The two replacement regimens were separated
by a 2-week washout period. Subjects were administered both patches and suppositories
(active or placebo, depending upon the treatment phase) daily throughout the entire
replacement period to ensure that the double blind was maintained. During the last week of
E, all women received 1 week of active P suppositories in addition to E to precipitate
menses. All women received prepackaged 1-week unit-dose supplies of suppositories that
were formulated and coded (weeks 1–5) by the NIH Pharmacy Department. All men
received 7.5 mg of depot Lupron by intramuscular injection every 4 weeks for 3 months.
Lupron alone was administered for the first 4 weeks. Subjects then received, in addition to
Lupron, testosterone enanthate (200 mg) or placebo (1 ml sesame oil) given by
intramuscular injection every 2 weeks for 1 month. All men received 1 month each of
testosterone replacement (T) and placebo. A placebo comparison was included in men to
blind the timing of the addition of testosterone, whereas in women no placebo phase was
included since the order of estradiol and progesterone addback was randomly assigned. In
both men and women the order of receiving hormone replacement (ie, T vs placebo in men,
and E vs P in women) was randomly assigned and counter-balanced.
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Figure 2.
In men, a significant interaction between baseline symptom group (high vs lo,w) and
hormone condition was identified by ANOVA-R (F2,20 = 9.7, p < 0.003). Men with high
baseline DISF scores (n = 6) had a significant reduction in total DISF scores during
hypogonadism compared with both baseline and T-replaced conditions, and a significant
increase in DISF scores after T replacement compared with hypogonadism. Men with low
baseline DISF scores (n = 6) showed no significant differences in DISF scores across
hormone conditions. Similarly, women with high baseline DISF scores (n = 6) showed a
significant reduction in DISF scores during hypogonadism (and during estrogen and
progesterone conditions) compared with baseline scores, whereas women with low baseline
DISF scores (n = 6) showed no significant change across hormone conditions (ANOVA-R
group × hormone condition, F3,30 = 9.8, p = 0.001). In women, total DISF scores were
significantly greater in the ‘high’ group at baseline only (t40 = 3.8, p < 0.01; otherwise p =
NS). Whereas, in men, total DISF scores were significantly higher in the ‘high’ compared to
the ‘low’ baseline symptom group during both baseline and T (t30 = 3.4 and 4.7,
respectively, p < 0.01). No significant interactions between subscale scores and group or
hormone condition were observed in either men or women.
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si
gn
ifi
ca
nt
ly
 d
ec
re
as
ed
 to
ta
l T
 le
ve
ls
 d
ur
in
g 
th
e 
hy
po
go
na
da
l
st
at
e 
as
 w
el
l a
s d
ur
in
g 
E 
an
d 
P 
(#
t 5
4 
= 
3.
4–
4.
8 
(r
an
ge
), 
p 
< 
0.
01
), 
w
ith
 n
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
s i
n 
to
ta
l T
 le
ve
ls
 b
et
w
ee
n 
E 
or
 P
 a
nd
 th
e 
hy
po
go
na
da
l s
ta
te
 (t
54
 =
 0
.7
–1
.1
 (r
an
ge
), 
p 
= 
N
S)
. E
st
ra
di
ol
 (E
)–
–
pl
as
m
a 
E 
le
ve
ls
 w
er
e 
si
gn
ifi
ca
nt
ly
 lo
w
er
 d
ur
in
g 
bo
th
 h
yp
og
on
ad
is
m
 a
nd
 P
 c
om
pa
re
d 
w
ith
 b
ot
h 
ba
se
lin
e 
an
d 
E 
(A
N
O
V
A
-R
 F
3,
54
 =
 2
0.
8,
 p
 <
 0
.0
01
; *
t 5
4 
= 
4.
0–
6.
6 
(r
an
ge
), 
p 
< 
0.
01
), 
w
he
re
as
 th
er
e 
w
er
e 
no
si
gn
ifi
ca
nt
 d
iff
er
en
ce
s b
et
w
ee
n 
ba
se
lin
e 
an
d 
E 
(t 5
4 
= 
2.
6,
 p
 <
 0
.1
 (t
re
nd
))
. P
ro
ge
st
er
on
e 
(P
)–
–P
 le
ve
ls
 w
er
e 
si
gn
ifi
ca
nt
ly
 h
ig
he
r d
ur
in
g 
P 
co
m
pa
re
d 
w
ith
 a
ll 
th
re
e 
ot
he
r h
or
m
on
e 
co
nd
iti
on
s (
A
N
O
V
A
-R
:
F 3
,5
4 
= 
27
.3
, p
 <
 0
.0
01
; +
t 5
4 
= 
7.
1–
7.
9 
(r
an
ge
), 
p 
< 
0.
01
). 
P 
le
ve
ls
 w
er
e 
no
t s
ig
ni
fic
an
tly
 d
iff
er
en
t a
cr
os
s b
as
el
in
e,
 h
yp
og
on
ad
is
m
, a
nd
 E
 c
on
di
tio
ns
 (t
54
 <
 1
.0
, p
 =
 N
S)
.
M
en
: b
lo
od
 le
ve
ls
 o
f t
ot
al
 te
st
os
te
ro
ne
 (t
ot
al
 T
) (
F 2
,3
8 
= 
71
.4
, p
 <
 0
.0
01
), 
fr
ee
 te
st
os
te
ro
ne
 (f
re
e 
T)
 (F
2,
38
 =
 9
7.
2,
 p
 <
 0
.0
01
), 
di
hy
dr
ot
es
to
st
er
on
e 
(D
H
T)
 (F
2,
38
 =
 3
3.
4,
 p
 <
 0
.0
01
) a
nd
 e
st
ra
di
ol
 (E
) (
F 2
,3
8
= 
30
.9
, p
 <
 0
.0
01
) w
er
e 
si
gn
ifi
ca
nt
ly
 lo
w
er
 d
ur
in
g 
hy
po
go
na
di
sm
 c
om
pa
re
d 
to
 b
ot
h 
ba
se
lin
e 
an
d 
T 
(#
to
ta
l T
, *
fr
ee
 T
, +
D
H
T,
 a
nd
 E
 (t
38
 =
 6
.2
–1
3.
2 
(r
an
ge
), 
p 
< 
0.
01
))
. B
lo
od
 h
or
m
on
e 
le
ve
ls
 d
id
 n
ot
 d
iff
er
be
tw
ee
n 
ba
se
lin
e 
an
d 
T 
(t 3
8 
= 
1.
4–
2.
5 
(r
an
ge
), 
p 
= 
N
S)
 a
lth
ou
gh
 th
er
e 
w
as
 a
 tr
en
d 
fo
r a
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 fr
ee
 T
 le
ve
ls
 b
et
w
ee
n 
ba
se
lin
e 
an
d 
T 
(t 3
8 
= 
2.
6,
 p
 =
 0
.0
5)
.
H
or
m
on
e 
as
sa
ys
: b
lo
od
 h
or
m
on
e 
le
ve
ls
 re
po
rte
d 
in
 th
is
 st
ud
y 
w
er
e 
m
ea
su
re
d 
in
 si
ng
le
 b
lo
od
 sa
m
pl
es
 o
bt
ai
ne
d 
du
rin
g 
th
e 
cl
in
ic
 v
is
it 
w
he
n 
th
e 
D
IS
F 
sc
al
e 
w
as
 c
om
pl
et
ed
.
In
 m
en
, s
er
um
 le
ve
ls
 o
f t
ot
al
 te
st
os
te
ro
ne
 (t
ot
al
 T
), 
fr
ee
 te
st
os
te
ro
ne
 (f
re
e 
T)
, e
st
ra
di
ol
 (E
), 
an
d 
di
hy
dr
ot
es
to
st
er
on
e 
(D
H
T)
 w
er
e 
m
ea
su
re
d 
by
 ra
di
oi
m
m
un
oa
ss
ay
 a
s d
es
cr
ib
ed
 p
re
vi
ou
sl
y 
(F
ur
uy
am
a 
et
 a
l,
19
70
; A
br
ah
am
, 1
97
3;
 V
er
m
eu
le
n 
et
 a
l, 
19
71
; A
br
ah
am
 e
t a
l, 
19
72
; J
ia
ng
 a
nd
 R
ya
n,
 1
96
9;
 It
o 
an
d 
H
or
to
n,
 1
97
0)
 b
y 
Q
ue
st
 D
ia
gn
os
tic
s (
B
al
tim
or
e,
 M
D
) a
nd
 C
ov
an
ce
 L
ab
or
at
or
ie
s (
V
ie
nn
a,
 V
A
). 
Th
e 
in
tra
-
an
d 
in
te
ra
ss
ay
 c
oe
ff
ic
ie
nt
s o
f v
ar
ia
tio
n 
w
er
e 
re
sp
ec
tiv
el
y 
5.
7 
an
d 
14
.0
%
 fo
r T
, 4
.4
 a
nd
 1
6.
9%
 fo
r f
re
e 
T,
 7
.7
 a
nd
 1
1.
0%
 fo
r E
, a
nd
 8
 a
nd
 9
%
 fo
r D
H
T.
In
 w
om
en
, s
er
um
 le
ve
ls
 o
f t
ot
al
 T
, E
, a
nd
 p
ro
ge
st
er
on
e 
(P
) w
er
e 
m
ea
su
re
d 
by
 ra
di
oi
m
m
un
oa
ss
ay
 a
s d
es
cr
ib
ed
 p
re
vi
ou
sl
y 
(F
ur
uy
am
a 
et
 a
l, 
19
70
; W
u 
an
d 
Lu
nd
y,
 1
97
1;
 It
o 
an
d 
H
or
to
n,
 1
97
0)
 b
y 
Es
ot
er
ix
(C
al
ab
as
as
 H
ill
, C
A
). 
Th
e 
in
tra
- a
nd
 in
te
ra
ss
ay
 c
oe
ff
ic
ie
nt
s o
f v
ar
ia
tio
n 
w
er
e 
re
sp
ec
tiv
el
y 
6.
6 
an
d 
8.
9%
 fo
r t
ot
al
 T
, 5
.5
 a
nd
 1
0.
9%
 fo
r E
, a
nd
 7
.5
 a
nd
 5
.8
%
 fo
r P
. F
re
e 
T 
an
d 
SH
B
G
 le
ve
ls
 w
er
e 
no
t p
er
fo
rm
ed
in
 w
om
en
 b
ec
au
se
 o
f t
he
 u
nr
el
ia
bi
lit
y 
of
 c
ur
re
nt
 a
ss
ay
s f
or
 m
ea
su
rin
g 
lo
w
 le
ve
ls
 o
f f
re
e 
T 
an
d 
SH
B
G
 in
 w
om
en
 (R
os
ne
r e
t a
l, 
20
07
).
Th
e 
la
bo
ra
to
ry
 n
or
m
al
 ra
ng
e 
fo
r t
he
 a
nd
ro
ge
n 
m
ea
su
re
s w
er
e 
as
 fo
llo
w
s:
 w
om
en
: t
ot
al
 T
 =
 1
0–
55
 n
g/
dl
; m
en
: t
ot
al
 T
 =
 2
60
–1
00
0 
ng
/d
l; 
fr
ee
 T
 =
 5
0–
12
0 
pg
/m
l; 
D
H
T 
= 
25
–7
5 
ng
/d
l.
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